Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. May 15, 2022; 14(5): 1002-1013
Published online May 15, 2022. doi: 10.4251/wjgo.v14.i5.1002
Published online May 15, 2022. doi: 10.4251/wjgo.v14.i5.1002
Figure 5 Receiver operating characteristic analysis of the albumin-to-alkaline phosphatase ratio, number of metastatic sites, and AAPR-M system in 1-year overall survival (A), 2-year overall survival (B), and 1-year progression-free survival (C) prediction.
PFS: Progression-free survival; OS: Overall survival; AAPR: Albumin-to-alkaline phosphatase ratio.
- Citation: Li YT, Zhou XS, Han XM, Tian J, Qin Y, Zhang T, Liu JL. Pretreatment serum albumin-to-alkaline phosphatase ratio is an independent prognosticator of survival in patients with metastatic gastric cancer. World J Gastrointest Oncol 2022; 14(5): 1002-1013
- URL: https://www.wjgnet.com/1948-5204/full/v14/i5/1002.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i5.1002